LifeArc Ventures — Full Portfolio

Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs.

BiotechHealthtechCambridge, GB

John McCafferty(Co-founder and CTO)inAneesh Karatt-Vellatt(Co-founder and CSO)in

Co-investorsMonograph Capital PartnersGeneral CatalystSolasta Ventures

Affect Therapeutics operates an app-based digital treatment provider offering care for substance use disorders (alcohol, cannabis, opioid) and mental health conditions like depression and anxiety, using methods such as contingency management, CBT, medication-assisted treatment, and peer support.

Digital HealthHealthtechMental HealthNew York, US

Jeff DeFlavio(Co-founder)inKristin Muhlner(Executive Officer, Director)in

BoardKevin Ryan(Director)Jeff Rinehart(Director)in

Co-investorsArtis VenturesCity LightAlleyCorpSamsung NextWhat If VenturesAllumia Ventures

Gene therapy company developing transformative medicines for neurodegenerative disorders.

Co-investorsF-Prime Capital

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

BiotechDeep TechDigital HealthHealthtech

Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)inDo Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)inLisa Deschamps(Chief Executive Officer)inGraeme Fielder(Chief Operating Officer)inAlex Bloom(Chief Development Officer)in

Co-investorsAdvent Life SciencesDementia DiscoveryF-Prime CapitalMonograph Capital PartnersNew Enterprise Associates (NEA)

Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia.

BiotechHealthtech

Aoife Brennan, MB, ChB(President and Chief Executive Officer)Perrin Wilson, PhD(Chief Business Officer)Susan Altschuller, PhD, MBA(Chief Financial Officer)Edgar Charles, MD(Chief Medical Officer)Ashley Jones(Senior Vice President, People & Workforce Strategy)Adam Villa, MBA, MS(Senior Vice President, Technical Operations)

Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.

BiotechDigital HealthHealthtechLongevity

Philip JaniakinMarie-Laure OzouxinRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin

Co-investorsFountain Healthcare PartnersJeito CapitalKurma PartnersOrbiMedV-Bio VenturesOmnes Capital+1 more

NeuLogiq is a research platform for clinical trials that integrates tablet-based cognitive assessments, EEG monitoring, and real-world behavioral data to measure brain function changes.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBelfast, GB

Brian Murphy(Co-Founder & CSO)inTina(CEO)

Co-investorsDementia Discovery FundClarendon Fund Managers Ltd.

Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.

BiotechHealthtech

Co-investorsCriteria Bio VenturesMedical Incubator Japan K.K.Modi VenturesPathway BioventuresSound Bioventures

Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease.

BiotechLeuven, BE

Co-investorsClavystBioFrazier Life SciencesNovo Holdings

Exciva is a company focused on neurological and neurodegenerative conditions, led by a team with expertise in chemistry, clinical operations, and regulatory affairs.

BiotechDigital HealthLongevityMedical DevicesHeidelberg, DE

Hans Moebius(Co-founder and CMO, Head of Clinical Operations)Anton Bespalov(Co-founder and CSO, Head of Regulatory Affairs)

Co-investorsAndera PartnersFountain Healthcare PartnersModi Ventures

Fluid Biomed develops a bioresorbable polymer-based stent designed to treat brain aneurysms by diverting blood flow and reducing risk of stroke.

BiotechDeep TechHealthtechMedical DevicesCalgary, CA

Dr. John H. Wong(Co-founder & Chief Executive Officer)Dr. Alim P. Mitha(Co-founder, President & Chief Technology Officer)

Co-investorsAccelerate FundShangBay Capital LLCThin Air LabsUCeed Funds

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)in

Co-investors5AM VenturesCatalio Capital Management, LPRoche Venture FundSixty Degree CapitalSofinnova PartnersAgent Capital+1 more

Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.

BiotechHealthtech

Co-investorsDroia VenturesFrazier Life Sciences

A UK-based preclinical biotechnology company developing antibody drugs against ion channels and GPCRs using proprietary KnotBody technology.

Co-investorsGeneral CatalystMonograph Capital Partners

MC Sciences is a biotech company developing first-in-class mast cell therapeutics based on a discovered mast cell receptor, aimed at diseases across immunology, dermatology, respiratory, gastrointestinal, fibrotic and chronic inflammatory conditions such as chronic urticaria, systemic mastocytosis, COPD, asthma and MCAS.

BiotechHealthtech

Gerhard J. Molderings(Founder)Wolfgang Taumann(CEO & Co-Founder)in

BoardMikael Dolsten(Board Chairman)

Co-investorsROC Venture Group

Ozlo manufactures sleep wellness products including blackout sleep masks and audio devices designed to improve sleep quality through light and sound control.

ConsumerHardwareWellness & Fitness

Co-investorsArtis Ventures

Developing PTD802, a therapeutic candidate for multiple sclerosis (received FDA IND clearance).

Co-investorsAdvent Life Sciences

Pheno Therapeutics is a clinical-stage biotech company developing GPR17 antagonists that target oligodendrocytes to promote brain repair.

BiotechMedical DevicesEdinburgh, GB

Neil Carragher(Founder)in

Co-investorsAdvent Life Sciences

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsFrazier Life Sciences

T-Cypher Bio develops drugs with curative potential, focusing on antibody development, T cell biology, and TCR discovery.

AI & Machine LearningBiotechDeep Tech

Co-investorsFuture Planet CapitalOxford Science EnterprisesPerivoli Innovations

Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.

BiotechHealthtech

Ole Kaasbøll(Co-founder)

Co-investorsHealthCapIndustrifondenInvestinorNovo Holdings